Cancer Nanotechnology

Cancer Nanotechnology

癌症纳米技术

  • 2区 中科院分区
  • Q1 JCR分区

期刊简介

《Cancer Nanotechnology》是由Springer Vienna出版社于2010年创办的英文国际期刊(ISSN: 1868-6958,E-ISSN: 1868-6966),该期刊长期致力于纳米科技领域的创新研究,主要研究方向为Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science。作为SCIE收录期刊(JCR分区 Q1,中科院 2区),本刊采用OA开放获取模式(OA占比1%),以发表纳米科技领域等方向的原创性研究为核心(研究类文章占比93.98%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在83篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动工程技术领域高水平交流平台。

投稿咨询

投稿提示

Cancer Nanotechnology审稿周期约为 15 Weeks 。该刊近年未被列入国际预警名单,年发文量约83篇,录用竞争适中,主题需确保紧密契合工程技术前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 工程技术 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 83 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊 综述期刊 大类学科 小类学科
工程技术
2区
NANOSCIENCE & NANOTECHNOLOGY 纳米科技 ONCOLOGY 肿瘤学
3区 3区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊 综述期刊 大类学科 小类学科
工程技术
2区
NANOSCIENCE & NANOTECHNOLOGY 纳米科技 ONCOLOGY 肿瘤学
3区 3区

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:NANOSCIENCE & NANOTECHNOLOGY SCIE Q2 61 / 140

56.8%

学科:ONCOLOGY SCIE Q1 78 / 322

75.9%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:NANOSCIENCE & NANOTECHNOLOGY SCIE Q2 50 / 140

64.64%

学科:ONCOLOGY SCIE Q2 109 / 322

66.3%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:5.2 SJR:0.671 SNIP:0.723
学科类别 分区 排名 百分位
大类:Pharmacology, Toxicology and Pharmaceutics 小类:Pharmaceutical Science Q2 68 / 183

63%

大类:Pharmacology, Toxicology and Pharmaceutics 小类:Physical and Theoretical Chemistry Q2 75 / 189

60%

大类:Pharmacology, Toxicology and Pharmaceutics 小类:Oncology Q2 163 / 404

59%

大类:Pharmacology, Toxicology and Pharmaceutics 小类:Biomedical Engineering Q2 128 / 303

57%

期刊发文

  • Low-dose pleiotropic radiosensitive nanoformulations for three-pronged radiochemotherapy of hypoxic brain glioblastoma under BOLD/DWI monitoring

    Author: Zhao, Fangshi; Wang, Xiaoyi; Zhu, Wei; Zhao, Dongju; Ye, Caihua; Guo, Yanyan; Dou, Yan

    Journal: CANCER NANOTECHNOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1186/s12645-023-00159-w

  • Bufalin-loaded vitamin E succinate-grafted chitosan oligosaccharide/RGD-conjugated TPGS mixed micelles inhibit intraperitoneal metastasis of ovarian cancer

    Author: Xu, Lan; Ma, Shuli; Fan, Bozhen; Yuan, Zeting; Yin, Peihao

    Journal: CANCER NANOTECHNOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1186/s12645-023-00178-7

  • Carbon nanoparticles-Fe(II) complex for efficient theranostics of xenografted colonic tumor

    Author: Xie, Ping; Huang, Yuanfang; Tang, Kexin; Wu, Xian; Zeng, Cheng; Yang, Sheng-Tao; Tang, Xiaohai

    Journal: CANCER NANOTECHNOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1186/s12645-023-00196-5

  • Boosting immunogenic cell death via hollow MnO2-based multiple stimuli-responsive drug delivery systems for improved cancer immunotherapy

    Author: Wu, Yueyao; Wang, Runtian; Shen, Peiliang; Zhou, Weijia; Chen, Chao; Yang, Kaiyong; Yang, Jingjing; Song, Yujun; Han, Xin; Guan, Xiaoxiang

    Journal: CANCER NANOTECHNOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1186/s12645-023-00173-y

  • Biological modeling of gadolinium-based nanoparticles radio-enhancement for kilovoltage photons: a Monte Carlo study

    Author: Wu, Jianan; Xu, Xiaohan; Liang, Ying; Chen, Tujia; Quan, Enzhuo; Wang, Luhua

    Journal: CANCER NANOTECHNOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1186/s12645-023-00202-w

  • Non-small cell lung cancer targeted nanoparticles with reduced side effects fabricated by flash nanoprecipitation

    Author: Wang, Mingwei; Huang, Haiyan; Zhong, Zilong; Chen, Xinyue; Fang, Yuan; Chen, Shenxin; Qi, Zhiyao; Yang, Danrong; Wang, Junyou; Bian, Wei

    Journal: CANCER NANOTECHNOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1186/s12645-023-00199-2

  • Reprogramming tumor microenvironment via dual targeting co-delivery of regorafenib and alpha-difluoromethylornithine in osteosarcoma

    Author: Wang, Hongsheng; Jin, Xinmeng; Gao, Yinghua; He, Xin; Xu, Yiming; Mu, Haoran; Jiang, Yafei; Wang, Zhuoying; Yu, Chen; Zhang, Tao; Hua, Yingqi; Cai, Zhengdong; Xu, Jing; Ma, Xiaojun; Sun, Wei

    Journal: CANCER NANOTECHNOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1186/s12645-023-00186-7

  • Monocytes reprogrammed by tumor microparticle vaccine inhibit tumorigenesis and tumor development

    Author: Sun, Weiwei; Dai, Lili; Cao, Yuqing; Pan, Pengtao; Zhi, Lijuan; Wang, Xinke; Yuan, Xinzhong; Gao, Zi; Guo, Sheng; Liu, Guoyan; Yin, Junlei; Xie, Liangliang; Wang, Liping; Wang, Yanling; Li, Wensheng; Li, Hong; Jia, Yunjie

    Journal: CANCER NANOTECHNOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1186/s12645-023-00190-x